Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Centessa Pharmaceuticals PLC

CNTA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: N/A

Last Close

$40.50

▲ +0.00%

Market Cap $6.27B · Vol 1.77M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.27B

Mid Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

73.72

Momentum

Beta

1.11

vs Market

52W High

$40.56

0.15% below

52W Low

$12.75

168.92% above

Volume

1.77M

Avg 331.60K

P/B

7.08

Price-to-book

ROE

-42.55%

Return on equity

Free Float

N/A

Public shares

Shariah Compliance8 STANDARDS

✗ Centessa Pharmaceuticals PLC (CNTA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CNTA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.89%

+45.21%

+57.71%

YTD

+61.94%

+185.21%

+486.11%

+69.31%

Financials & Valuation

TTM · Annual

Total Revenue	$15.00M
Net Income	$-197,532,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-1,384.61%
Net Profit Margin	-1,316.88%
ROE	-42.55%
ROA · ROIC	-30.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	226.28
P/B	7.08
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	154.73M

Technical Indicators

50-Day SMA	$39.71
200-Day SMA	$29.33
RSI (14)	73.72
Beta	1.11
52-Week High	$40.56
52-Week Low	$12.75

Volume Today	1.77M
Avg Daily Volume (30D)	331.60K
Relative Volume	5.35x
Volatility (10D)	4.41
Volatility (30D)	3.49
Free Float	N/A

Analyst Consensus

N/A

Current Price $40.50

Mean Target N/A

52W Low$12.75 52W High$40.56

Current

Target

$12.75 $40.56

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01081FC68

ISINUS1523091007

CountryUnited Kingdom

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.